Legend Biotech Corporation
(NASDAQ: LEGN)
Balfour Capital Group has issued a buy recommendation
for Legend Biotech Corporation (LEGN) on December 29th, 2023
Legend Biotech Corporation (LEGN) is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing novel cell therapies for oncology and other indications. Founded in 2014 and headquartered in Somerset, New Jersey, it operates as a subsidiary of Genscript Biotech Corporation.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $60.17 on December 29th, 2023.
- Our designated price target stands at $120.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Legend Biotech Corporation (NASDAQ: LEGN) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
